Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes

Abstract Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenit...

Full description

Saved in:
Bibliographic Details
Main Authors: Anick Bérard, Shannon Strom, Jin-Ping Zhao, Shashi Kori, Detlef Albrecht
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
R
Q
Online Access:https://doaj.org/article/8872f81c01f84aba9c5de34e563332be
Tags: Add Tag
No Tags, Be the first to tag this record!